

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Guidance development

MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified. Equality considerations include: pregnant women, children difficult to sedate and elderly. Pregnancy and age are protected characteristics. The clinical experts explained that in pregnant women, especially in the first trimester, the use of volatile anaesthetics involve clinical judgment in the risk/benefit balance to the unborn foetus and risk to the woman. This is stated in section 4.7 of the MTCD. Volatile anaesthesia may particularly benefit children for whom sedation is difficult. Volatile anaesthesia may benefit elderly people who are considered vulnerable to excess or insufficient sedation, due to their reduced ability to eliminate and excrete drugs, may benefit from this technology through sedation becoming more easily monitored and titrated.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No further equality issues were highlighted in the submission or patient organisation questionnaires.

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No other potential equality issues were identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

No.

Approved by Associate Director: Anastasia Director

Date: 12/8/2021

Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No potential equality issues were raised. Additional considerations were added for people with chronic wounds that take longer than 12 months to heal or may never heal. This has been discussed in section 4.6 of the guidance.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

The recommendations have changed after consultation, but they do not make it more difficult in practice for a specific group to access the technology compared with other groups.

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in

questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the medical technology guidance document, and, if so, where?

The committee considerations surrounding equality considerations can be found in section 4.6 of the draft guidance.

Approved by Programme Director:

Date: